Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. / Hemmingsen, Bianca; Lund, Søren S; Wetterslev, Jørn; Vaag, Allan.

I: European Journal of Endocrinology, Bind 161, Nr. 1, 2009, s. 1-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hemmingsen, B, Lund, SS, Wetterslev, J & Vaag, A 2009, 'Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes', European Journal of Endocrinology, bind 161, nr. 1, s. 1-9. https://doi.org/10.1530/EJE-09-0167

APA

Hemmingsen, B., Lund, S. S., Wetterslev, J., & Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. European Journal of Endocrinology, 161(1), 1-9. https://doi.org/10.1530/EJE-09-0167

Vancouver

Hemmingsen B, Lund SS, Wetterslev J, Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. European Journal of Endocrinology. 2009;161(1):1-9. https://doi.org/10.1530/EJE-09-0167

Author

Hemmingsen, Bianca ; Lund, Søren S ; Wetterslev, Jørn ; Vaag, Allan. / Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. I: European Journal of Endocrinology. 2009 ; Bind 161, Nr. 1. s. 1-9.

Bibtex

@article{2952ff5068c711df928f000ea68e967b,
title = "Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes",
abstract = "This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.",
author = "Bianca Hemmingsen and Lund, {S{\o}ren S} and J{\o}rn Wetterslev and Allan Vaag",
note = "Keywords: Administration, Oral; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Prevalence; Risk Factors Export Date: 4 November 2009Source: Scopus",
year = "2009",
doi = "10.1530/EJE-09-0167",
language = "English",
volume = "161",
pages = "1--9",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

AU - Hemmingsen, Bianca

AU - Lund, Søren S

AU - Wetterslev, Jørn

AU - Vaag, Allan

N1 - Keywords: Administration, Oral; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Prevalence; Risk Factors Export Date: 4 November 2009Source: Scopus

PY - 2009

Y1 - 2009

N2 - This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.

AB - This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.

U2 - 10.1530/EJE-09-0167

DO - 10.1530/EJE-09-0167

M3 - Journal article

C2 - 19369429

VL - 161

SP - 1

EP - 9

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -

ID: 19979293